

**Department of Planning and Budget
2025 General Assembly Session
State Fiscal Impact Statement**

PUBLISHED: 2/20/2025 12:28 PM

ORIGINAL

Bill Number: SB1135 ER

Patron: Boysko

Bill Title: Crystalline polymorph psilocybin; regulations for prescribing, etc.

Bill Summary: Directs the Board of Pharmacy to promulgate regulations that allow for prescribing, dispensing, possessing, distributing, transporting, and using the pharmaceutical composition of crystalline polymorph psilocybin upon approval by the U.S. Food and Drug Administration and following rescheduling by the U.S. Drug Enforcement Administration.

Budget Amendment Necessary: No

Items Impacted: n/a

Explanation: This bill is not expected to create a fiscal impact, nor does it require that language changes be made to the proposed Appropriation Act.

Fiscal Summary: There is no anticipated state fiscal impact resulting from this bill.

Fiscal Analysis: Upon approval of the pharmaceutical use of crystalline polymorph psilocybin by the U.S. Food and Drug Administration and rescheduling by the U.S. Drug Enforcement Administration, the Board of Pharmacy will be required to vote on amending and promulgating regulations at its next quarterly meeting. Such actions are not expected to have an impact on existing resources, given that they are proposed to take place as part of the standard meeting schedule for the Board.

Other: n/a